Usynova Pharmaceuticals Ltd.

This study tests a new oral medication (a TYK2 inhibitor) for people with moderate to severe plaque psoriasis. About 140 adults aged 18-70 will receive either the drug or a placebo for 12 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75%.

This early-stage study tests whether a new tablet called UA026 is safe and how it works in the body. It involves 124 people, including healthy volunteers and those with moderate to severe plaque psoriasis. The goal is to find the right dose and check for side effects, not yet to …